Clinical Trials · NCT05669599
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Amgen
- Enrollment
- 592
- Start date
- Jan 2023
- Locations
- 78 sites, 12 countries
- Primary endpoint
- Percent Change From Baseline to Week 52 in Body Weight